At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06872 TENNOR THERAP-B
Not Yet Opened 10-21 16:08:18
100.700
-2.400
-2.33%
High110.000
Low100.000
Vol20.70K
Open110.000
D1 Closing103.100
Amplitude9.70%
Mkt Cap5.27B
Tradable Cap5.27B
Total Shares52.33M
T/O2.14M
T/O Rate0.04%
Tradable Shares52.33M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
TenNor Therapeutics Keeps Share Capital Steady at 52.33 Million H Shares in September 2026
Tennor Therapeutics Reports Positive Phase Iia Poc Data for Rifaquizinone (Tnp-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
Tennor Therapeutics (Suzhou) Ltd is a China-based company primarily engaged in the discovery and development of innovative drug products. The Company focuses on the fields of bacterial infections and bacterial metabolism diseases. The Company's products include Rifasutenizol (TNP-2198), a novel molecular entity candidate for the treatment of Helicobacter pylori, Rifaquizinone (TNP-2092) injection, a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections and TNP-2092 oral, multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.